Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
Martin L. Sos(German Cancer Research Center), Roman K. Thomas(University of Cologne), Kathrin Michel(Max Planck Society), Samanthi A. Perera(Dana-Farber/Harvard Cancer Center), Kwok‐Kin Wong(NYU Langone Health), Sascha Ansén, Rameen Beroukhim(Broad Institute), Isabel Stückrath(Max Planck Society), Hamid Kashkar(University of Cologne), Johannes M. Heuckmann, William R. Sellers(Broad Institute), William Pao(Albany Medical Center Hospital), Matthäus Getlik(Max Planck Society), Katerina Politi(Yale Cancer Center), Roland T. Ullrich(University of Cologne), Martin Peifer(University of Cologne), Daniel Rauh(TU Dortmund University), Thomas Zander(Integrated Oncology (United States)), Kevan M. Shokat(Howard Hughes Medical Institute), Lukas C. Heukamp(Institut für Hämatopathologie Hamburg), Stefanie Heynck, Lucía Regales(Memorial Sloan Kettering Cancer Center), Mirjam Koker(Massachusetts General Hospital), Stefanie Fischer(Max Planck Society), Lori S. Friedman, Florian Fischer(Max Planck Society), Aviva Goel(Memorial Sloan Kettering Cancer Center), Jonathan M. Weiss(Max Planck Institute for Metabolism Research), Christine Orr(Exelixis (United States)), Klaus P. Hoeflich(Pivot)
Cited by 255
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k